IDEC-C2B8 chimeric anti-CD20 antibody (MAB): Safety and clinical activity in the treatment of patients (PTS) with relapsed low-grade or follicular (IWF:A-D) non-Hodgkin's lymphoma (NHL)

被引：0
|
作者：
GrilloLopez, AJ [1 ]
Varns, C [1 ]
Waldichuk, C [1 ]
Dallaire, BK [1 ]
Rosenberg, J [1 ]
McClure, A [1 ]
Shen, D [1 ]
机构：
[1] IDEC PHARMACEUT CORP,SAN DIEGO,CA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 1996年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1072 / 1072
页数：1
相关论文
共 50 条
  • [21] Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma
    Tobinai, K
    Kobayashi, Y
    Narabayashi, M
    Ogura, M
    Kagami, Y
    Morishima, Y
    Ohtsu, T
    Igarashi, T
    Sasaki, Y
    Kinoshita, T
    Murate, T
    ANNALS OF ONCOLOGY, 1998, 9 (05) : 527 - 534
  • [22] IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group
    M. Feuring-Buske
    M. Kneba
    M. Unterhalt
    A. Engert
    M. Gramatzki
    E. Hiller
    L. Trümper
    W. Brugger
    H. Ostermann
    J. Atzpodien
    M. Hallek
    E. Aulitzky
    W. Hiddemann
    Annals of Hematology, 2000, 79 : 493 - 500
  • [23] Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody
    Maeda, T
    Yamada, Y
    Tawara, M
    Yamasaki, R
    Yakata, Y
    Tsutsumi, C
    Onimaru, Y
    Kamihira, S
    Tomonaga, M
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2001, 74 (01) : 70 - 75
  • [24] IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas:: results of a phase-II study of the German Low-Grade Lymphoma Study Group
    Feuring-Buske, M
    Kneba, M
    Unterhalt, M
    Engert, A
    Gramatzki, M
    Hiller, E
    Trümper, L
    Brugger, W
    Ostermann, H
    Atzpodien, J
    Hallek, M
    Aulitzky, E
    Hiddemann, W
    ANNALS OF HEMATOLOGY, 2000, 79 (09) : 493 - 500
  • [25] Successful Treatment With a Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab) for a Patient With Relapsed Mantle Cell Lymphoma Who Developed a Human Anti-Chimeric Antibody
    Takahiro Maeda
    Yasuaki Yamada
    Masayuki Tawara
    Reishi Yamasaki
    Yuichi Yakata
    Chizuko Tsutsumi
    Yasuyuki Onimaru
    Simeru Kamihira
    Masao Tomonaga
    International Journal of Hematology, 2001, 74 : 70 - 75
  • [26] RITUXAN(TM) (rituximab, IDEC-C2B8): Interim analysis of a phase II study of once weekly times 8 dosing in patients with relapsed low-grade or follicular non-Hodgkin's lymphoma.
    Piro, L
    White, CA
    Lopez, AJG
    Janakiraman, N
    Beck, TM
    Selander, K
    Dowden, S
    Czuczman, M
    Lynch, JW
    Kolitz, JE
    Jain, V
    BLOOD, 1997, 90 (10) : 2272 - 2272
  • [27] IDEC-C2B8 anti-CD20 antibody: Results of long-term follow-up of relapsed NHL phase II trial patients
    Maloney, DG
    GrilloLopez, AJ
    Bodkin, D
    White, C
    Foon, K
    Schilder, RJ
    Neidhart, J
    Janakiraman, N
    Waldichuk, C
    Davis, T
    Dallaire, BK
    Royston, I
    Levy, R
    BLOOD, 1995, 86 (10) : 205 - 205
  • [28] Anti-CD20 monoclonal antibody (rituximab) associated to mine and autotransplantation in patients with relapsed or primary refractary follicular or transformed follicular non-Hodgkin lymphoma (NHL).
    Solano, C
    Gutiérrez, AM
    Benet, I
    Marugán, I
    Tormo, M
    Terol, MJ
    Prósper, F
    García-Conde, J
    BLOOD, 1999, 94 (10) : 406B - 406B
  • [29] Human-mouse chimeric 131I-labeled anti-CD20 monoclonal antibody (MAB) in relapsed non-Hodgkin's lymphoma (NHL):: Dosimetry and radioimmunotherapy (RIT).
    Scheidhauer, K
    Baumgartl, HJ
    von Schilling, C
    Schmidt, B
    Wolf, I
    Reidel, G
    Peschel, C
    Schwaiger, M
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 268P - 268P
  • [30] Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
    Demidem, A
    Lam, T
    Alas, S
    Hariharan, K
    Hanna, N
    Bonavida, B
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1997, 12 (03) : 177 - 186
12345